These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12667118)

  • 21. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
    Fossella FV
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The current status of docetaxel for advanced non-small cell lung cancer.
    Green MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
    Ng R; Loreto M; Lee R; Leighl NB
    Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel in advanced non-small cell lung cancer.
    Wakelee H; Ramalingam S; Belani CP
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
    Bunn PA; Chan DC; Earle K; Zhao TL; Helfrich B; Kelly K; Piazza G; Whitehead CM; Pamukcu R; Thompson W; Alila H
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):87-94. PubMed ID: 11894018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
    Mattson K
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
    Fossella FV; Rigas J
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):9-12. PubMed ID: 10458204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
    Donnellan PP; Crown JP
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG).
    Cerny T; Kaplan S; Pavlidis N; Schöffski P; Epelbaum R; van Meerbeek J; Wanders J; Franklin HR; Kaye S
    Br J Cancer; 1994 Aug; 70(2):384-7. PubMed ID: 7914429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.
    Smyth JF; Smith IE; Sessa C; Schoffski P; Wanders J; Franklin H; Kaye SB
    Eur J Cancer; 1994; 30A(8):1058-60. PubMed ID: 7654428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
    Gandara DR; Edelman MJ; Lau D
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
    Mattson K; Saarinen A; Jekunen A
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
    Ho JC; Tan EH; Leong SS; Wang CH; Sun Y; Li R; Wahid MI; Jusuf A; Liao M; Guan Z; Handoyo P; Huang JS; Chan V; Luna G; Tsang KW; Lam WK;
    Respir Med; 2003 Jul; 97(7):796-803. PubMed ID: 12854629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
    Manegold C
    Onkologie; 2003 Dec; 26 Suppl 7():26-32. PubMed ID: 14716139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.